Orelabrutinib - CISMeF

Preferred Label : Orelabrutinib;

NCIt synonyms : BTK Inhibitor ICP-022;

NCIt definition : A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.;

UNII : WJA5UO9E10;

InChIKey : MZPVEMOYADUARK-UHFFFAOYSA-N;

CAS number : 1655504-04-3;

Molecule name : ICP 022; ICP-022;

NCI Metathesaurus CUI : CL563002;

Details

Origin ID

C156173;

UMLS CUI

C5418257;

Currated CISMeF NLP mapping
- orelabrutinib [MeSH Supplementary Concept]
- orelabrutinib [MeSH concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- orelabrutinib [MeSH Supplementary Concept]
- orelabrutinib [ATC Code]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Tyrosine-Protein Kinase BTK [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients